Gain Therapeutics, Inc
Price
FilingsNewest: 8-K, Other eventsOct 1 →InsidersNo open-market buys or sales.→HoldersMarshall Wace, LLP 4.4%Potomac 2.2%Dme 1.3%→Financing →PeersClosest companies: SEPN, ALT, RLAY→
From the filings
Figures
- Net income
- −$20.1Mlast 12 months
- Operating cash flow
- −$19.4Mlast 12 months
- Cash and equivalents
- $13.1Mat the last balance sheet
- Total debt
- $343,686at the last balance sheet
- Shares outstanding
- 43.3M shareson issue